More than 1,000 clinical trials were stopped by the pandemic — including dozens in PhIII
We’ve been hearing plenty of anecdotal evidence of the damage done by the Covid-19 outbreak globally to drug R&D. But a researcher now based in Berlin trawled the data available online and came up with a startling conclusion: at least 1,099 trials have been halted by the coronavirus.
The vast majority of these studies — 97%, or 1,070 — were suspended, a temporary halt that could allow them to resume once the new virus has been tamed and sites reopened. But it may not be that simple.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.